Anadis [ASX: ANX] is to begin commercialisation of BioGard, a treatment designed to maintain gastrointestinal and immune system health.

The treatment, aimed at people undergoing antiretroviral therapy for HIV/AIDS, will be marketed as medical food.

BioGard's active ingredient is a formulation of antigen-targeted Bovine Clostrum Powder (BCP). The cows from which the powder is sourced will be vaccinated with a mixture of lipopolysaccarides implicated as key drivers of AIDS pathogenesis.

It will at first be made available in tablet form, sold over-the-counter but intended for use under medical supervision.

The product's ingredients and manufacturing process has been approved by the TGA.